文献速递心脑血管急症重症综合管理与镇静镇痛

氯胺酮启动后难治性癫痫持续状态终止的相关因素:多变量分析模型

Factors Associated with Refractory Status Epilepticus Termination Following Ketamine Initiation: A Multivariable Analysis Model.
PubMed 文献 · Neurocrit Care · 2022-08-24
一句话结论单中心回顾性研究显示,81例难治性癫痫持续状态患者加用氯胺酮后60.5%永久终止,氯胺酮负荷量与缺氧负相关,液体超负荷发生率28.4%。

该单中心回顾性观察研究纳入10年间879例接受静脉氯胺酮的患者,其中81例用于治疗癫痫持续状态(SE)。81例中49例(60.5%)实现SE永久终止,36例(44.4%)归因于氯胺酮作为最后使用的药物(氯胺酮相关终止,AC)。多变量分析显示,既往癫痫病史与有效药物反应相关(OR 3.19,95%CI 0.83-12.67,p=0.09);在AC组中,氯胺酮启动延迟与SE终止相关(p=0.077);较长的SE持续时间(p=0.04)、给予氯胺酮负荷量(p=0.03)和缺氧(p=0.007)与AC负相关;给予氯胺酮负荷量(p=0.02)和缺氧(p=0.009)与总体SE终止负相关。氯胺酮对脑血流动力学无显著影响,但观察到液体超负荷(28.4%)。

要点

  • 81例难治性SE患者加用静脉氯胺酮后,49例(60.5%)实现SE永久终止,其中36例(44.4%)归因于氯胺酮作为最后药物。
  • 给予氯胺酮负荷量与氯胺酮相关终止负相关(p=0.03),也与总体SE终止负相关(p=0.02)。
  • 缺氧与氯胺酮相关终止负相关(p=0.007),也与总体SE终止负相关(p=0.009)。
  • 在氯胺酮相关终止组中,氯胺酮启动延迟与SE终止相关(p=0.077)。
  • 氯胺酮对脑血流动力学无显著影响,但28.4%的患者出现液体超负荷。

适用人群与场景

  • 接受静脉氯胺酮治疗的癫痫持续状态患者(81例),来自10年间879例接受静脉氯胺酮的患者。

处置流程与药物剂量

  • 静脉给予氯胺酮,包括负荷量(推注)和持续输注;原文未写明具体剂量、输注速度及疗程。

红旗征与不能漏的情况

  • 缺氧与氯胺酮相关终止(p=0.007)及总体SE终止(p=0.009)负相关。
  • 液体超负荷发生率为28.4%。

研究设计与关键结果

  • 研究类型:回顾性、大样本、单中心、观察性研究,历时10年;纳入879例接受静脉氯胺酮的患者,其中81例用于治疗SE。
  • 主要终点:SE永久终止49/81(60.5%);氯胺酮相关终止(AC)36/81(44.4%)。
  • 既往癫痫病史与有效药物反应:OR 3.19(95%CI 0.83-12.67,p=0.09)。
  • 在AC组中,氯胺酮启动延迟与SE终止相关(p=0.077)。
  • 与AC负相关的因素:较长SE持续时间(p=0.04)、给予氯胺酮负荷量(p=0.03)、缺氧(p=0.007)。
  • 与总体SE终止负相关的因素:给予氯胺酮负荷量(p=0.02)、缺氧(p=0.009)。
  • 不良事件:氯胺酮对脑血流动力学无显著影响;液体超负荷见于28.4%的患者。

证据类型、等级与局限

  • 证据类型:回顾性、单中心、观察性研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 该单中心回顾性观察性研究显示,加用氯胺酮后SE永久终止率较高(60.5%),但给予负荷量和缺氧与终止率负相关,液体超负荷为预期并发症(28.4%);作者认为需关注液体超负荷。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: In this study, we identify factors associated with ketamine success in the treatment of refractory status epilepticus (SE). We also evaluate for adverse events including systemic and cerebral hemodynamic stability and fluid volume overload.

METHODS: In this retrospective, large, single-center, observational study over a 10-year period, 879 consecutive patients receiving intravenous (IV) ketamine were reviewed, and 81 patients were identified as receiving IV ketamine for the treatment of SE. Descriptive analysis was done to determine treatment response and adverse events in patients receiving IV ketamine for SE. Multivariable logistic regression analyses were fitted to determine prediction models for seizure cessation.

RESULTS: Permanent cessation of SE was achieved in 49 of 81 (60.5%) of patients for whom ketamine was part of the treatment plan. Of those, 36 (44.4%) were attributed to ketamine as the last drug used (ketamine-associated cessation [AC]). Prior history of epilepsy had an odds ratio of 3.19 (confidence interval 0.83-12.67, p = 0.09) associated with efficacious medication response. Increased latency to ketamine was associated with cessation of SE specifically in patients in the AC group (p = 0.077). Longer SE duration (p = 0.04), administration of ketamine loading dose (bolus; p = 0.03), and anoxia (p = 0.007) were negatively associated with AC. Administration of ketamine loading dose (p = 0.02) and anoxia (p = 0.009) were negatively associated with overall SE cessation. There was no significant impact of ketamine on cerebral hemodynamics, but evidence of fluid volume overload was seen (28.4% of patients).

CONCLUSIONS: Our cohort is a large observational study showing a high success rate of permanent cessation of SE after the addition of ketamine. Using multivariable analysis, we demonstrate a significant association with seizure cessation in patients with prior history of epilepsy and those with prolonged latency to ketamine initiation. Furthermore, we describe the impact of fluid volume overload as an anticipated complication with ketamine use.

来源:Neurocrit Care,查看原文。版权归原作者所有。

参考来源

  1. Srinivas M, Parker D, Millis S, et al. Factors Associated with Refractory Status Epilepticus Termination Following Ketamine Initiation: A Multivariable Analysis Model. Neurocrit Care. 2022. PMID: 36002634. doi:10.1007/s12028-022-01578-0

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。